Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Aug 22, 2022--
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Aug 22, 2022--